CDKN1A and neoplasm: Finally, we observed that T-ALL onset was accelerated by 37 days in Cdkn1a-deficient mice (Figure 6G), compared to the 53 day acceleration found in Heb/Tcf12+/- mice, confirming a tumor-suppressor function for Cdkn1a (Figure 6G).